Show simple item record

dc.contributor.authorBateman, Eric D
dc.contributor.authorPrice, David
dc.contributor.authorWang, Hao-Chien
dc.contributor.authorSchonffeldt, Patricia
dc.contributor.authorCatanzariti, Angelina
dc.contributor.authorvan der Valk, Ralf J.P.
dc.contributor.authorBeekman, Maarten J.H.I.
dc.date.accessioned2023-10-20T23:15:51Z
dc.date.available2023-10-20T23:15:51Z
dc.date.issued2022-06-09
dc.identifier212037314
dc.identifierc1d8c6c3-0d24-4487-bbd8-7dc24b8af2a8
dc.identifier85131770700
dc.identifier.citationBateman , E D , Price , D , Wang , H-C , Schonffeldt , P , Catanzariti , A , van der Valk , R J P & Beekman , M J H I 2022 , ' Reply to : Cause or consequence? ' , European Respiratory Journal , vol. 59 , no. 6 , 2200103 . https://doi.org/10.1183/13993003.00103-2022en
dc.identifier.issn0903-1936
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/19859
dc.descriptionFunding AstraZeneca funded the SABINA III study; was involved in the study design, protocol development, study conduct and statistical analysis; and was given the opportunity to review this manuscript before submission. Publication support was provided by Michelle Rebello, PhD, of Cactus Life Sciences and funded by AstraZeneca.en
dc.format.extent2
dc.format.extent187879
dc.format.extent255255
dc.language.isoeng
dc.relation.ispartofEuropean Respiratory Journalen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectasthmaen
dc.subjectprescriptionen
dc.subjectshort acting β2-agonisten
dc.subjectR Medicineen
dc.subject.lccRen
dc.titleReply to : Cause or consequence?en
dc.typeJournal itemen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.description.statusPeer revieweden
dc.identifier.doihttps://doi.org/10.1183/13993003.00103-2022
dc.identifier.vol59en
dc.identifier.iss6en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record